×
About 2,043 results

ALLMedicine™ Chordoma Center

Research & Reviews  725 results

Outcomes of Recurrent Mobile Spine Chordomas.
https://doi.org/10.5435/JAAOS-D-22-00621
The Journal of the American Academy of Orthopaedic Surgeons; Kolz JM, Wellings EP et. al.

Feb 3rd, 2023 - Chordomas of the mobile spine are rare malignant tumors. The purpose of this study was to review the outcomes of treatment for patients with recurrent mobile spine chordomas. The oncologic outcomes and survival of 30 patients undergoing treatment ...

Skull-Base Chordoma Mimicking Optic Neuritis.
https://doi.org/10.1097/WNO.0000000000001575
Journal of Neuro-ophthalmology : the Official Journal of ... Ali AA, Dashti F et. al.

Feb 3rd, 2023 - Skull-Base Chordoma Mimicking Optic Neuritis.|2023|Ali AA,Dashti F,Behbehani RS,|

Clival Chordomas in the Endoscopic Endonasal Era: Comparison With Management With Open ...
https://doi.org/10.1227/neu.0000000000002286
Neurosurgery Schnurman Z, Benjamin CG et. al.

Feb 3rd, 2023 - The most significant paradigm shift in surgical management of skull base chordomas has been the adoption of the endoscopic endonasal approach, but the impact on patient outcomes compared with open skull base approaches remains unclear. To compare ...

A Prospective Study of Surgical Treatment Strategies for Chordoma
https://clinicaltrials.gov/ct2/show/NCT05707767

Feb 1st, 2023 - Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.

Technical aspects of total spondylectomy of C2.
https://doi.org/10.23736/S0390-5616.21.05443-6
Journal of Neurosurgical Sciences; Stulik J, Klezl Z et. al.

Jan 28th, 2023 - Tumorous involvement of the second cervical vertebra is an infrequent, but severe disease. Primary tumors and solitary metastases can be addressed by a radical procedure, a complete removal of the whole compartment. The second cervical vertebra ha...

see more →

Guidelines  1 results

Bone cancer.
https://doi.org/10.6004/jnccn.2013.0088
Journal of the National Comprehensive Cancer Network : JN... Biermann JS, Adkins DR et. al.

Jun 8th, 2013 - Primary bone cancers are extremely rare neoplasms, accounting for fewer than 0.2% of all cancers. The evaluation and treatment of patients with bone cancers requires a multidisciplinary team of physicians, including musculoskeletal, medical, and r...

see more →

Clinicaltrials.gov  40 results

A Prospective Study of Surgical Treatment Strategies for Chordoma
https://clinicaltrials.gov/ct2/show/NCT05707767

Feb 1st, 2023 - Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes
https://clinicaltrials.gov/ct2/show/NCT01200680

Jan 26th, 2023 - Synopsis Background: Chordoma is a rare, slow growing, often fatal bone cancer derived from remnants of the embryonic notochord. It occurs mostly in the axial skeleton (skull base, vertebrae, sacrum and coccyx), is more frequent in males than fema...

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
https://clinicaltrials.gov/ct2/show/NCT02601950

Jan 19th, 2023 - This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemeto...

The Effect of USG-Guided Coccygeal Nerve Block on Sacrococcygeal and/or Intercoccygeal Joint Injection for Coccydynia
https://clinicaltrials.gov/ct2/show/NCT05683262

Jan 13th, 2023 - Coccydynia refers to a significant pain, that does not radiate, in and around the coccyx region. This symptom is typically worsen while sitting, especially on hard surfaces, standing up from sitting position and standing for a long time. There are...

Children and Adults With Chordoma
https://clinicaltrials.gov/ct2/show/NCT03910465

Dec 8th, 2022 - Background: Chordomas are a rare tumor with an incidence of 325 new cases per year in the United States. Pediatric chordomas are very rare and comprise only 5% of all chordoma cases. The standard therapy for localized primary or recurrent chordoma...

see more →

News  35 results

Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas
https://www.onclive.com/view/durvalumab-plus-tremelimumab-elicits-favorable-pfs-rates-in-advanced-sarcomas

Aug 23rd, 2022 - The combination of durvalumab (Imfinzi) and tremelimumab demonstrated positive progression-free survival (PFS) and overall survival (OS) rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas, accor...

Treating Bone and Soft Tissue Sarcomas
https://www.onclive.com/view/treating-bone-and-soft-tissue-sarcomas

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Breelyn A. Wilky, MD Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL Determining the best course of treatment for sarcomas of the bone and soft tissues is a c...

Dr. Chi on Response to Tazemetostat in Children With INI1-Negative Tumors
https://www.onclive.com/view/dr-chi-on-response-to-tazemetostat-in-children-with-ini1negative-tumors

Oct 6th, 2021 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses response to tazemetostat in children with INI1-negative...

Dr. Chi on Tazemetostat in Pediatric Patients With INI1-Negative Tumors
https://www.onclive.com/view/dr-chi-on-tazemetostat-in-pediatric-patients-with-ini1negative-tumors

Oct 6th, 2021 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the EZH2 inhibitor tazemetostat in pediatric patients w...

Dr. Chi Discusses Tazemetostat Trial in INI1-Negative Pediatric Tumors
https://www.onclive.com/view/dr-chi-discusses-tazemetostat-trial-in-ini1negative-pediatric-tumors

Oct 6th, 2021 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1...

see more →

Patient Education  16 results see all →